These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 7984827)

  • 1. Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: pathogenesis and treatment.
    Koski CL
    Semin Neurol; 1994 Jun; 14(2):123-30. PubMed ID: 7984827
    [No Abstract]   [Full Text] [Related]  

  • 2. The mechanism of action of intravenous immunoglobulin in patients with chronic inflammatory demyelinating polyneuropathy.
    Brand A; Van Doorn PA; Rossi F; Kazatchkine MD; Vermeulen M
    Prog Clin Biol Res; 1990; 337():405-9. PubMed ID: 2353004
    [No Abstract]   [Full Text] [Related]  

  • 3. Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: immune mechanisms and update on current therapies.
    van der Meché FG; van Doorn PA
    Ann Neurol; 1995 May; 37 Suppl 1():S14-31. PubMed ID: 8968214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy.
    Barohn RJ; Saperstein DS
    Semin Neurol; 1998; 18(1):49-61. PubMed ID: 9562667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A critical review of therapies in acute and chronic inflammatory demyelinating polyneuropathies.
    Pollard JD
    Muscle Nerve; 1987; 10(3):214-21. PubMed ID: 3031499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated serum levels of endothelial leukocyte adhesion molecules in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy.
    Oka N; Akiguchi I; Kawasaki T; Ohnishi K; Kimura J
    Ann Neurol; 1994 May; 35(5):621-4. PubMed ID: 7513983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gm haplotypes in inflammatory demyelinating polyneuropathies.
    Feeney DJ; Pollard JD; McLeod JG; Stewart GJ; De Lange GG
    Ann Neurol; 1989 Dec; 26(6):790-2. PubMed ID: 2557797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Future developments in the treatment of immune-mediated polyneuropathies.
    van der Meché FG; van Doorn PA
    Eur Neurol; 1997; 38(3):230-7. PubMed ID: 9363836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Acquired demyelinating neuropathies].
    Hahn AF
    Rev Prat; 2000 Apr; 50(7):724-30. PubMed ID: 10853551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Inflammatory and immunologically-induced diseases of the peripheral nerves].
    Wiethölter H; Dichgans J
    Internist (Berl); 1984 Oct; 25(10):599-606. PubMed ID: 6094383
    [No Abstract]   [Full Text] [Related]  

  • 11. Immune mechanisms in acute and chronic inflammatory polyneuropathies.
    Toyka KV; Hartung HP; Schäfer B; Heininger K; Fierz W
    J Neuroimmunol; 1988 Dec; 20(2-3):277-81. PubMed ID: 2848862
    [No Abstract]   [Full Text] [Related]  

  • 12. Chronic immune demyelinating neuropathies.
    Lopate G; Pestronk A
    Semin Neurol; 1994 Jun; 14(2):131-6. PubMed ID: 7527153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum interleukin-2 concentrations in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis.
    Hartung HP; Reiners K; Schmidt B; Stoll G; Toyka KV
    Ann Neurol; 1991 Jul; 30(1):48-53. PubMed ID: 1929228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA antigens in the Landry-Guillain-Barré syndrome and chronic relapsing polyneuritis.
    Stewart GJ; Pollard JD; McLeod JG; Wolnizer CM
    Ann Neurol; 1978 Sep; 4(3):285-9. PubMed ID: 718142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of chronic immune-mediated polyneuropathies. State of the art and perspectives].
    Léger JM; Chassande B
    Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S19-23. PubMed ID: 10896984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum antibodies to heparan sulfate glycosaminoglycans in Guillain-Barré syndrome and other demyelinating polyneuropathies.
    Pestronk A; Choksi R; Yee WC; Kornberg AJ; Lopate G; Trotter J
    J Neuroimmunol; 1998 Nov; 91(1-2):204-9. PubMed ID: 9846837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Dysimmune neuropathies: current diagnosis and therapy].
    Léger JM; Larue S; Dashi F
    Rev Prat; 2008 Nov; 58(17):1887-9, 1892-4. PubMed ID: 19157204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Experiences with high dosage immunoglobulin G in neuromuscular diseases].
    Schuchardt V; Hotz M; Hund E; Sun S; Heitmann R; Hacke W
    Nervenarzt; 1993 Feb; 64(2):98-103. PubMed ID: 8450901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization and risk of relapse of Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy.
    Hughes RA; Choudhary PP; Osborn M; Rees JH; Sanders EA
    Muscle Nerve; 1996 Sep; 19(9):1230-1. PubMed ID: 8761286
    [No Abstract]   [Full Text] [Related]  

  • 20. [Recent aspects of acute and chronic inflammatory polyneuropathies: Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy].
    Pascual-Pascual SI
    Rev Neurol; 2002 Aug 1-15; 35(3):269-76. PubMed ID: 12235589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.